^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    NM28-2746

    i
    Other names: NM28-2746, NM28, biMSLN.CD3.hSA
    Associations

    News

    Trials
    Company:
    3SBio, Numab
    Drug class:
    CD3 agonist, Mesothelin inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin. (PubMed, Oncoimmunology)
    In xenograft models, NM28-2746 exhibited significant tumor suppressing activity, which was significantly enhanced by combination therapy with NM21-1480. NM28-2746, alone or in combination with NM21-1480, may overcome shortcomings of previous MSLN-targeted immuno-oncology drugs, exhibiting enhanced discrimination of high MSLN-expressing cell activity in the presence of sMSLN.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    MSLN (Mesothelin)
    |
    MSLN expression
    |
    NM21-1480 • NM28-2746